JMP Securities Maintains Market Outperform on AN2 Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on AN2 Therapeutics (NASDAQ:ANTX) but lowers the price target from $6 to $3.

August 09, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on AN2 Therapeutics but lowers the price target from $6 to $3.
The Market Outperform rating suggests a positive outlook, but the lowered price target indicates reduced expectations for short-term gains. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100